On 16 December, Novo Nordisk A/S, a Danish multinational pharmaceutical company developing innovative biological medicines, announced that it plans to initiate a Phase III clinical trial in Alzheimer’s disease (AD) with its drug semaglutide in the first half of 2021.
The company intends to enrol approximately 3,700 research participants with early AD to investigate the efficacy and safety of once-daily oral semaglutide (14mg), compared to placebo. Oral semaglutide (7 mg and 14 mg) is approved as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes in the US, EU and Japan.